Who owns CGEM?
Institutional ownership of Cullinan Therapeutics Inc. from Form 13F, Q2 2026
184 institutional managers reported holding Cullinan Therapeutics Inc. (CGEM) in Form 13F filings for Q2 2026, with 71,706,606 shares worth $1.3B. The largest reported holder was MPM Bioimpact LLC. Managers that filed both quarters added a net 6,130,851 shares (+9.4%). 29 opened new positions and 20 sold out.
- Funds holding
- 184
- Value held
- $1.3B
- New / sold out
- 29 / 20
- Net shares, same filers
- +9.4%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of CGEM
| Fund | Value | Share of 13F holdings | Shares | Move |
|---|---|---|---|---|
| MPM Bioimpact LLC | $177M | 13.6% | 9,731,341 | Added |
| Lynx1 Capital Management LP | $163M | 12.5% | 8,963,500 | Unchanged |
| BVF Inc | $105M | 8.0% | 5,750,683 | Unchanged |
| BlackRock, Inc. | $95.3M | 7.3% | 5,232,766 | Added |
| Price T Rowe Associates Inc | $69.7M | 5.3% | 3,825,950 | Added |
| State Street Corp | $66.8M | 5.1% | 3,668,627 | Added |
| Kynam Capital Management, LP | $56.7M | 4.3% | 3,114,132 | Unchanged |
| Vanguard Capital Management LLC | $47.6M | 3.6% | 2,614,066 | Added |
| RTW Investments, LP | $43.1M | 3.3% | 2,364,347 | Added |
| Siren, L.L.C. | $34.5M | 2.6% | 1,893,410 | Added |
| Geode Capital Management, LLC | $28.2M | 2.2% | 1,547,309 | Added |
| Blue Owl Capital Holdings LP | $28.0M | 2.1% | 1,539,764 | Trimmed |
| Venrock Adviser, LLC | $25.1M | 1.9% | 1,379,965 | Unchanged |
| Boothbay Fund Management, LLC | $19.7M | 1.5% | 1,082,611 | Trimmed |
| Dimensional Fund Advisors LP | $19.1M | 1.5% | 1,046,694 | Added |
| Goldman Sachs Group Inc | $18.2M | 1.4% | 1,001,598 | Added |
| Affinity Asset Advisors, LLC | $15.9M | 1.2% | 875,760 | Added |
| Vanguard Portfolio Management LLC | $13.5M | 1.0% | 738,741 | Added |
| Boone Capital Management LLC | $12.8M | 1.0% | 704,442 | New |
| Elmind Capital, LP | $12.6M | 1.0% | 690,000 | Added |
| Morgan Stanley | $11.5M | 0.9% | 629,035 | Added |
| Twin Focus Capital Partners, LLC | $10.8M | 0.8% | 595,489 | Unchanged |
| AQR Capital Management LLC | $10.6M | 0.8% | 581,338 | Added |
| Northern Trust Corp | $10.4M | 0.8% | 571,080 | Added |
| Bank of America Corp | $9.3M | 0.7% | 510,325 | Trimmed |
Share of 13F holdings is each fund's shares as a share of the 71,706,606 CGEM shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- MPM Bioimpact LLC Added+$37.9M
- Price T Rowe Associates Inc Added+$32.7M
- State Street Corp Added+$20.5M
- BlackRock, Inc. Added+$14.3M
- Boone Capital Management LLC New+$12.8M
- Siren, L.L.C. Added+$12.7M
- RTW Investments, LP Added+$12.0M
- Goldman Sachs Group Inc Added+$9.9M
- Perceptive Advisors LLC New+$7.8M
- Adage Capital Partners GP, L.l.c. New+$4.3M
Biggest sellers in Q2 2026
- Marshall Wace, LLP Trimmed-$17.9M
- Nextech Invest Ltd. Sold out-$16.2M
- Point72 Asset Management, L.P. Trimmed-$15.1M
- Blue Owl Capital Holdings LP Trimmed-$6.7M
- Soleus Capital Management, L.P. Trimmed-$6.6M
- Nuveen, LLC Trimmed-$6.1M
- Deerfield Management Company, L.p. Sold out-$5.5M
- Two Sigma Investments, LP Trimmed-$4.5M
- Orbimed Advisors LLC Sold out-$3.5M
- Schroder Investment Management Group Sold out-$2.3M
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $223M and sold $102M; 84 added and 46 trimmed.
Schedule 13D and 13G filings on CGEM
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-11-10STATE STREET CORP SCHEDULE 13G filed by Cullinan Therapeutics Inc.Schedule 13G
- 2026-08-14PRICE T ROWE ASSOCIATES INC /MD/ SCHEDULE 13G filed by Cullinan Therapeutics Inc.Schedule 13G
- 2026-08-07STATE STREET CORP SCHEDULE 13G filed by Cullinan Therapeutics Inc.Schedule 13G
- 2026-03-04Kynam Capital Management, LP SCHEDULE 13G filed by Cullinan Therapeutics Inc.Schedule 13G
- 2026-01-30VANGUARD GROUP INC SCHEDULE 13G filed by Cullinan Therapeutics Inc.Schedule 13G
- 2025-08-06CITADEL ADVISORS LLC SCHEDULE 13G filed by Cullinan Therapeutics Inc.Schedule 13G
Questions about CGEM ownership
- Who owns CGEM stock?
- 184 institutional investment managers reported CGEM positions in their Form 13F filings for Q2 2026, holding 71,706,606 shares worth $1.3B in total. MPM Bioimpact LLC reported the largest position.
- Are funds buying or selling CGEM?
- In Q2 2026, 29 managers opened new CGEM positions, 84 added, 46 trimmed and 20 sold out. Managers that filed in both quarters added a net 6,130,851 shares.
- How current is this CGEM institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to CGEM by CUSIP. Options are left out. CGEM news and filings · CGEM insider trades · Top funds